Activated Recombinant Factor VIIa should not be used in patients with refractory variceal bleeding – it is mostly ineffective is expensive and may rarely cause serious adverse events

摘要

>Activated Recombinant Factor VIIa Does Not Improve Mortality in Variceal Bleeding. Bendtsen F, D’Amico G, Rusch E, de Franchis R, Anderson PK, Lebrec D, et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials. J Hepatol 2014; 61: 252–259. (>Reproduced with Permission)Background & AimsTwo randomized controlled studies have evaluated the effect of recombinant Factor VIIa (rFVIIa) on variceal bleeding in cirrhosis without showing significant benefit. The aim of the present study was to perform a meta-analysis of the two trials on individual patient data with special focus on high risk patients.